Comparative Pharmacology
Head-to-head clinical analysis: CEFUROXIME SODIUM IN PLASTIC CONTAINER versus KEFLET.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEFUROXIME SODIUM IN PLASTIC CONTAINER versus KEFLET.
CEFUROXIME SODIUM IN PLASTIC CONTAINER vs KEFLET
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cefuroxime is a beta-lactam cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell lysis and death. It has bactericidal activity against susceptible organisms.
Keflet (warfarin) inhibits vitamin K epoxide reductase, preventing the recycling of vitamin K and thereby reducing the synthesis of clotting factors II, VII, IX, and X in the liver.
1.5 g IV every 8 hours for moderate to severe infections; may be increased to 3 g IV every 8 hours for severe or life-threatening infections.
500 mg orally every 12 hours for 10-14 days; for uncomplicated UTI: 250 mg orally every 12 hours for 7 days.
None Documented
None Documented
Terminal elimination half-life: 1.2-1.9 hours. Prolonged in renal impairment (up to 15-20 hours with CrCl <20 mL/min).
0.5-1 hour; prolonged in renal impairment (up to 20-30 hours in ESRD).
Renal excretion: 80-90% unchanged by glomerular filtration and tubular secretion. Biliary/fecal: <10%.
Renal (80-90% unchanged via glomerular filtration and tubular secretion); biliary/fecal < 5%.
Category A/B
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic